WO2011149126A1 - Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function - Google Patents
Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function Download PDFInfo
- Publication number
- WO2011149126A1 WO2011149126A1 PCT/KR2010/003332 KR2010003332W WO2011149126A1 WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1 KR 2010003332 W KR2010003332 W KR 2010003332W WO 2011149126 A1 WO2011149126 A1 WO 2011149126A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- tyrosine kinase
- kinase inhibiting
- inhibiting function
- inflammatory compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Abstract
The present invention relates to a pharmaceutical composition which contains an active ingredient in the form of an anti-inflammatory compound having a tyrosine kinase inhibiting function, and the compound according to the present invention can suppress the activities of various tyrosine kinases, and can be used to advantage in the prevention or treatment of inflammatory diseases, autoimmune diseases and the like associated therewith.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2010/003332 WO2011149126A1 (en) | 2010-05-26 | 2010-05-26 | Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function |
ES11786920.6T ES2647586T3 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound that has inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing the same |
JP2013512543A JP5613323B2 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing the same |
PCT/KR2011/003873 WO2011149288A2 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
US13/699,970 US9062066B2 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same |
DK11786920.6T DK2578590T3 (en) | 2010-05-26 | 2011-05-26 | ANTI-INFLAMMATORY RELATIONSHIP WITH INHIBITORIAL ACTIVITY AGAINST MULTIPLE TYROSINKINASAS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
CN201180026042.7A CN102971327B (en) | 2010-05-26 | 2011-05-26 | There is the anti-inflammatory compound of multiple tyrosine-kinase enzyme inhibition activity and the pharmaceutical compositions containing these compounds |
KR1020127030670A KR101478302B1 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same |
HUE11786920A HUE035589T2 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
EP11786920.6A EP2578590B1 (en) | 2010-05-26 | 2011-05-26 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2010/003332 WO2011149126A1 (en) | 2010-05-26 | 2010-05-26 | Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011149126A1 true WO2011149126A1 (en) | 2011-12-01 |
Family
ID=45004106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/003332 WO2011149126A1 (en) | 2010-05-26 | 2010-05-26 | Pharmaceutical composition comprising an anti-inflammatory compound having a tyrosine kinase inhibiting function |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011149126A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492383B1 (en) * | 1997-11-11 | 2002-12-10 | Pfizer Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
WO2007056214A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
-
2010
- 2010-05-26 WO PCT/KR2010/003332 patent/WO2011149126A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492383B1 (en) * | 1997-11-11 | 2002-12-10 | Pfizer Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
WO2007056214A2 (en) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof |
Non-Patent Citations (1)
Title |
---|
BOSCHELLI, D.H. ET AL.: "Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)-amino]-2-heteroaryl-thieno[3,2-b] pyridine-6-carbonitriles", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, 2005, pages 4681 - 4684 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012046030A3 (en) | Phosphodiesterase inhibitors | |
WO2011162515A3 (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
WO2008094737A3 (en) | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
WO2012021715A3 (en) | Stable formulations of linaclotide | |
MX2010014041A (en) | A crystalline form of posaconazole. | |
WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
WO2013185082A3 (en) | Inhibitors of bruton's tyrosine kinase | |
NZ745210A (en) | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor | |
WO2012101653A3 (en) | Modified release pharmaceutical compositions memantine | |
MX2009011952A (en) | Compounds and compositions as c-kit and pdgfr kinase inhibitors. | |
WO2011149288A2 (en) | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same | |
WO2011126250A3 (en) | Composition containing pde5 inhibitor for relieving skin wrinkles | |
WO2014141210A3 (en) | Multifunctional immature dental pulp stem cells and therapeutic applications | |
WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
WO2011141488A3 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
WO2011121576A3 (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
WO2011159137A3 (en) | Novel thiourea or urea derivative, preparation method thereof, and pharmaceutical composition for preventing or treating aids, containing same as active ingredient | |
WO2014160775A8 (en) | Compositions and methods for the treatment of malaria | |
AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
WO2011149301A3 (en) | A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases | |
WO2011150457A3 (en) | Haematopoietic-prostaglandin d2 synthase inhibitors | |
WO2011088160A3 (en) | Novel cyp17 inhibitors | |
MX344189B (en) | Formulations of mazindol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10852212 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.03.2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10852212 Country of ref document: EP Kind code of ref document: A1 |